Taysha Gene Therapies, Inc.
NASDAQ:TSHABiotechnology
+$0.10 today
- Market cap
- $1.22B
- Beta
- 1.18
- P/E (TTM)
- -17.7
- EPS (TTM)
- -$0.35
Volume 2.17M
Average 2.73M
Returns on capital
Taysha Gene Therapies, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-44.1%
avg -2455.1%
ROIC
-34.9%
avg 65.2%
ROA
-31.7%
avg -1116.4%
Analysis
ROA is currently the strongest return metric at -31.7% versus its period average of -1116.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Sean Nolan | Chief Executive Officer & Chairman | USD 1.19M | 58 | — | — |
Sukumar Nagendran | President, Head of Research & Development and Director | USD 1.04M | 59 | 936.41K | 0.33% |
Kamran Alam | Chief Financial Officer & Corporate Secretary | USD 741.9K | 48 | 1.44M | 0.50% |
Berge Minassian | Chief Medical Advisor of UT Southwestern Gene Therapy Program | — | — | — | — |
Hayleigh Collins | Director of Corporate Communications & Investor Relations | — | — | — | — |
Frederick Porter | Chief of Staff & Technical Operations Officer | — | — | — | — |
Michael Johannesen | Chief Legal Officer & Corporate Secretary | — | 60 | — | — |
Sean McAuliffe | Chief Business Officer | — | — | — | — |
Emily McGinnis | Chief Patient & External Affairs Officer | — | — | — | — |
Steven Gray | Chief Scientific Advisor of UT Southwestern Gene Therapy Program | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 10, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
12
$6.66M
Net Transaction Value
−$6.66M
Net selling
Most Active
Nagendran Sukumar
7 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jul 10, 26Jul 10, 2026 | Nagendran Sukumar Direct | Sell | $1.2M$1,248,000.00 |
| Apr 10, 26Apr 10, 2026 | Nagendran Sukumar Direct | Sell | $892K$892,000.00 |
| Feb 4, 26Feb 4, 2026 | Alam Kamran Direct | Sell | $7.5K$7,480.60 |
| Jan 26, 26Jan 26, 2026 | Nolan Sean P. Direct | Sell | $190.4K$190,448.32 |
| Jan 26, 26Jan 26, 2026 | Nagendran Sukumar Direct | Sell | $124.1K$124,091.98 |
| Jan 26, 26Jan 26, 2026 | Alam Kamran Direct | Sell | $109.9K$109,943.89 |
| Jan 23, 26Jan 23, 2026 | Nolan Sean P. Direct | Sell | $649.7K$649,747.75 |
| Jan 23, 26Jan 23, 2026 | Nagendran Sukumar Direct | Sell | $423.4K$423,377.00 |
| Jan 23, 26Jan 23, 2026 | Alam Kamran Direct | Sell | $375.1K$375,098.00 |
| Jan 12, 26Jan 12, 2026 | Nagendran Sukumar Direct | Sell | $942K$942,000.00 |
1–10 of 12
Summary
Insiders reported 0 buys worth $0.00 and 12 sells worth $6.66M over the last 12 months. That adds up to net selling of $6.66M. Nagendran Sukumar was the most active insider with 7 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +57.5% | +154.3% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at +57.5% over three years. Forward estimates point to Revenue at +154.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Taysha Gene Therapies, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about TSHA's management, answered from reported figures.
Who manages TSHA?
Taysha Gene Therapies, Inc. (TSHA) lists 10 active executives. The top listed executive is Berge Minassian, Chief Medical Advisor of UT Southwestern Gene Therapy Program.
Are TSHA insiders buying or selling?
Recent insider activity shows net buying of $53.40M.
Continue the stock analysis
Jump to another research area for this company.